1. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Beau M M, Beran M, Tallman M S, Ebert B L, Kantarjian H M, Stone R M, Gilliland D G, Crispino J D, Levine R L:
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood, 114: 144-147 (2009)
2. Ahn J-S, Kim H-J, Kim Y-K, Jung S-H, Yang D-H, Lee J-J, Lee I-K, Kim N Y, Minden M D, Jung C W, Jang J-H, Kim H J, Moon J H, Sohn S K, Won J-H, Kim S-H, Kim N, Yoshida K, Ogawa S, Kim D D H: Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. Haematologica, 100: e351-e353 (2015)
3. Arber D A, Orazi A, Hasserjian R, Thiele J, Borowitz M J, Le Beau M M, Bloomfield C D, Cazzola M, Vardiman J W: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127: 2391-2405 (2016)
4. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S: Implications of NRAS mutations in AML: a study of 2502 patients. Blood, 107: 3847-3853 (2006)
5. Becker H, Marcucci G, Maharry K, Radmacher M D, Mrózek K, Margeson D, Whitman S P, Wu Y-Z, Schwind S, Paschka P, Powell B L, Carter T H, Kolitz J E, Wetzler M, Carroll A J, Baer M R, Caligiuri M A, Larson R A, Bloomfield C D: Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression signatures: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 28: 596-604 (2010) 6. Bennett J M, Catovsky D, Daniel M-T, Flandrin G, Galton D A, Gralnick H
R, Sultan C: Proposals for the classification of the acute leukaemias
French-American-British (FAB) co-operative group. British Journal of Haematology, 33: 451-458 (1976)
7. Bloomfield C D, Marcucci G, Döhner K, Döhner H: Introduction: Acute Myeloid Leukemia. Seminars in Oncology, 35: 324-325 (2008)
8. Breems D A, Putten W L V, Greef G E D, Zelderen-Bhola S L V, Gerssen-Schoorl K B, Mellink C H, Nieuwint A, Jotterand M, Hagemeijer A, Beverloo H B, Löwenberg B: Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. Journal of Clinical Oncology, 26: 4791-4797 (2008)
9. Büchner T, Berdel W E, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland M-C, Heinecke A, Wörmann B, Hiddemann W: Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. Journal of Clinical Oncology, 27: 61-69 (2009)
10. Burnett A K, Russell N H, Hills R K, Bowen D, Kell J, Knapper S, Morgan Y G, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMulli M F, Hunter A, Clark R E, Grimwade D: Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology, 16: 1295-1305 (2015)
11. Buscarlet M, Provost S, Zada Y F, Barhdadi A, Bourgoin V, Lépine G, Mollica L, Szuber N, Dubé M-P, Busque L: DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood, 130: 753-762 (2017)
12. Byrd J C, Mrózek K, Dodge R K, Carroll A J, Edwards C G, Arthur D C, Pettenati M J, Patil S R, Rao K W, Watson M S, Koduru P R K, Moore J O, Stone R M, Mayer R J, Feldman E J, Davey F R, Schiffer C A, Larson R A, Bloomfield C D: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in
adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100: 4325-4336 (2002) 13. Cancer Genome Atlas Research Network: Genomic and epigenomic
landscapes of adult de novo acute myeloid leukemia. New England Journal of Medicine, 368: 2059-2074 (2013)
14. Chiba S: Dysregulation of TET2 in hematologic malignancies. International Journal of Hematology, 105: 17-22 (2017)
15. Chou W-C, Chou S-C, Liu C-Y, Chen C-Y, Hou H-A, Kuo Y-Y, Lee M-C, Ko B-S, Tang J-L, Yao M, Tsay W, Wu S-J, Huang S-Y, Hsu S-C, Chen Y-C, Chang Y-C, Kuo Y-Y, Kuo K-T, Lee F-Y, Liu M-C, Liu C-W, Tseng M-H, Huang C-F, Tien H-F: TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood, 118: 3803-3810 (2011)
16. Cimmino L, Dawlaty M M, Ndiaye-Lobry D, Yap Y S, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S, Verma A K, Jaenisch R, Aifantis I: TET1 is a tumor suppressor of hematopoietic malignancy. Nature Immunology, 16: 653-662 (2015)
17. Damm F, Markus B, Thol F, Morgan M, Göhring G, Schlegelberger B, Krauter J, Heuser M, Bernard O A, Ganser A: TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns. Genes, Chromosomes and Cancer, 53: 824-832 (2014)
18. De Kouchkovsky I, Abdul-Hay M: Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer Journal, 6: e441 (2016)
19. Delhommeau F, Dupont S, Valle V D, James C, Trannoy S, Masse A, Kosmider O, Le Couedic J-P, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus F J, Marzac C, Casadevall N, Lacombe C, Romana S P, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard O A: Mutation in TET2 in myeloid cancers. New England Journal of Medicine, 360: 2289-2301 (2009)
20. Deschler B, Lübbert M: Acute myeloid leukemia: epidemiology and etiology.
Cancer, 107: 2099-2107 (2006)
21. Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S: Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood, 110: 1308-1316 (2007) 22. DiNardo C D, Jonas B, Pullarkat V, Thirman M, Garcia J, Wei A, Döhner H,
Fenaux P, Recher C, Konopleva M, Fiedler W, Koller E, Havelange V, Schuh A, Esteve J, Wang J, Vrhovac R, Hajek R, Porkka K, Illes A, Wolach O, Olivieri A, Yamamoto K, Jang J-H, Juliusson G, Vorobyev V, Yeh S-P, Ozcan M, Hong W-J, Zhou Y, Potluri J, Pratz K: A randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naïve patients with acute myeloid leukemie ineligible for intensive therapy-viale-a. EHA Library, abstract LB2601 (14.6.2020)
23. DiNardo C D, Pratz K, Pullarkat V, Jonas B A, Arellano M, Becker P S, Frankfurt O, Konopleva M, Wei A H, Kantarjian H M, Xu T, Hong W-J, Chyla B, Potluri J, Pollyea D A, Letai A: Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Blood, 133: 7-17 (2019)
24. DiNardo C D, Stein E M, de Botton S, Roboz G J, Altman J K, Mims A S, Swords R, Collins R H, Mannis G N, Pollyea D A, Donnellan W, Fathi A T, Pigneux A, Erba H P, Prince G T, Stein A S, Uy G L, Foran J M, Traer E, Stuart R K, Arellano M L, Slack J L, Sekeres M A, Willekens C, Choe S, Wang H, Zhang V, Yen K E, Kapsalis S M, O.T.R., Yang H, Dai D, Fan B, Goldwasser M, Sc.D., Liu H, Agresta S, Wu B, Attar E C, Tallman M S, Stone R M, Kantarjian H M: Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. New England Journal of Medicine, 378:
2386-2398 (2018)
25. Döhner H, Estey E H, Amadori S, Appelbaum F R, Büchner T, Burnett A K, Dombret H, Fenaux P, Grimwade D, Larson R A, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele G J, Sanz M A, Sierra J, Tallman M S, Löwenberg B, Bloomfield C D: Diagnosis and management of acute myeloid
leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115: 453-474 (2010)
26. Döhner H, Estey E H, Grimwade D, Amadori S, Appelbaum F R, Büchner T, Dombret H, Ebert B L, Fenaux P, Larson R A, Levine R L, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele G J, Sanz M, Sierra J, Tallman M S, Tien H-F, Wei A H, Löwenberg B, Bloomfield C D: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 129: 424-447 (2017)
27. Döhner H, Gaidzik V I: Impact of genetic features on treatment decisions in AML. Hematology, 2011: 36-42 (2011)
28. Döhner H, Weisdorf D J, Bloomfield C D: Acute myeloid leukemia. New England Journal of Medicine, 373: 1136-1152 (2015)
29. Döhner K, Paschka P, Döhner H: Akute myeloische Leukämie. Der Internist, 56: 354-363 (2015)
30. Döhner K, Döhner H: Molecular characterization of acute myeloid leukemia.
Haematologica, 93: 976-982 (2008)
31. Dombret H, Seymour J F, Butrym A, Wierzbowska A, Selleslag D, Jang J H, Kumar R, Cavenagh J, Schuh A C, Candoni A, Récher C, Sandhu I, del Castillo T B, Al-Ali H K, Martinelli G, Falantes J, Noppeney R, Stone R M, Minden M D, McIntyre H, Songer S, Lucy L M, Beach C L, Döhner H:
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts. Blood, 126:
291-299 (2015)
32. Downward J: Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer, 3: 11-22 (2003)
33. Falini B, Martelli M P, Bolli N, Sportoletti P, Liso A, Tiacci E, Haferlach T:
Acute myeloid leukemia with mutated nucleophosmin (NPM1): Is it a distinct entity? Blood, 117: 1109-1120 (2011)
34. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, Starza R L, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci P-G, Martelli M F: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine, 352: 254-266 (2005)
35. Fenaux P, Mufti G J, Hellströom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List A F, Gore S, Seymour J F, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman L R: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Journal of Clinical Oncology, 28: 562-569 (2010)
36. Figueroa M E, Abdel-Wahab O, Lu C, Ward P S, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez H F, Tallman M S, Sun Z, Wolniak K, Peeters J K, Liu W, Choe S E, Fantin V R, Paietta E, Löwenberg B, Licht J D, Godley L A, Delwel R, Valk P J M, Thompson C B, Levine R L, Melnick A: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Cancer Cell, 18: 553-567 (2010)
37. Fisher C L, Lee I, Bloyer S, Bozza S, Chevalier J, Dahl A, Bodner C, Helgason C D, Hess J L, Humphries R K, Brock H W: Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. Developmental Biology, 337: 9-15 (2010)
38. Fröhling S, Scholl C, Gilliland D G, Levine R L: Genetics of myeloid malignancies: pathogenetic and clinical implications. Journal of Clinical Oncology, 23: 6285-6295 (2005)
39. Gaidzik V I, Bullinger L, Schlenk R F, Zimmermann A S, Röck J, Paschka P, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, others: RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic
and clinical analysis from the AML study group. Journal of Clinical Oncology, 29: 1364-1372 (2011)
40. Gaidzik V I, Paschka P, Späth D, Habdank M, Köhne C-H, Germing U, von Lilienfeld-Toal M, Held G, Horst H-A, Haase D, Bentz M, Götze K, Döhner H, Schlenk R F, Bullinger L, Döhner K: TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. Journal of Clinical Oncology, 30: 1350-1357 (2012) 41. Gaidzik V I, Schlenk R F, Moschny S, Becker A, Bullinger L, Corbacioglu A,
Krauter J, Schlegelberger B, Ganser A, Döhner H, Döhner K: Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia:
a study of the German-Austrian AML Study Group. Blood, 113: 4505-4511 (2009)
42. Gaidzik V I, Schlenk R F, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs H G, Kremers S, Greil R, Raghavachar A, Ringhoffer M, Salih H R, Wattad M, Kirchen H G, Runde V, Heil G, Petzer A L, Girschikofsky M, Heuser M, Kayser S, Goehring G, Teleanu M-V, Schlegelberger B, Ganser A, Krauter J, Bullinger L, Döhner H, Döhner K:
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood, 121:
4769-4777 (2013)
43. Gaidzik V I, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne C H, Horst H A, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus J M, Kestler H A, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk R F, Döhner K, Döhner H: RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia, 30: 2160-2168 (2016)
44. Genovese G, Kähler A K, Handsaker R E, Lindberg J, Rose S A, Bakhoum S F, Chambert K, Mick E, Neale B M, Fromer M, Purcell S M, Svantesson O, Landén M, Höglund M, Lehmann S, Gabriel S B, Moran J L, Lander E S, Sullivan P F, Sklar P, Grönberg H, Hultman C M, McCarroll S A: Clonal
hematopoiesis and blood-cancer risk inferred from blood DNA sequence.
New England Journal of Medicine, 371: 2477-2487 (2014)
45. Gilliland D G, Jordan C T, Felix C A: The molecular basis of leukemia.
Hematology, 2004: 80-97 (2004)
46. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood, 92: 2322-2333 (1998)
47. Grisendi S, Mecucci C, Falini B, Pandolfi P P: Nucleophosmin and cancer.
Nature Reviews Cancer, 6: 493-505 (2006)
48. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, Yoshida K, Roller A, Nadarajah N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler H P, Klein H-U, Dugas M, Aburatani H, Kohlmann A, Miyano S, Haferlach C, Kern W, Ogawa S: Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia, 28: 241-247 (2014)
49. Heuser M, Thol F, Ganser A: Klonale Hämatopoese von unbestimmtem Potenzial. Deutsches Ärzteblatt, 113: 317-322 (2016)
50. Hills R K, Castaigne S, Appelbaum F R, Delaunay J, Petersdorf S, Othus M, Estey E H, Dombret H, Chevret S, Ifrah N, Cahn J-Y, Récher C, Chilton L, Moorman A V, Burnett A K: Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
The Lancet Oncology, 15: 986-996 (2014)
51. https://clinicaltrials.gov/ct2/show/NCT03897127 (7.7.2020) 52. https://clinicaltrials.gov/ct2/show/NCT04027309 (7.7.2020)
53. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman P V, B.A., Mar B G, Lindsley R C, Mermel C H, Burtt N, Chavez A, Higgins J M, Moltchanov V, Kuo F C, Kluk M J, Henderson B, Koistinen L K H A, Ladenvall C, Getz
G, Correa A, Banahan B F, Gabriel S, Kathiresan S, Stringham H M, McCarthy M I, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson J G, Neuberg D, Altshuler D, Ebert B L: Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine, 371: 2488-2498 (2014)
54. Juliusson G, Antunovic P, Derolf Å, Lehmann S, Möllgård L, Stockelberg D, Tidefelt U, Wahlin A, Höglund M: Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood, 113: 4179-4187 (2009)
55. Kao H W, Liang D C, Kuo M C, Wu J H, Dunn P, Wang P N, Lin T L, Shih Y S, Liang S T, Lin T H, Lai C Y, Lin C H, Shih L Y: High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
Oncotarget, 6: 33217-33225 (2015)
56. Kato N, Kitaura J, Doki N, Komeno Y, Watanabe-Okochi N, Togami K, Nakahara F, Oki T, Enomoto Y, Fukuchi Y, Nakajima H, Harada Y, Harada H, Kitamura T: Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models. Blood, 117: 221-233 (2011)
57. Kayser S, Levis M J: FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. Leukemia & Lymphoma, 55:
243-255 (2014)
58. Ko M, An J, Bandukwala H S, Chavez L, Äijö T, Pastor W A, Segal M F, Li H, Koh K P, Lähdesmäki H, Hogan P G, Aravind L, Rao A: Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature, 497: 122-126 (2013)
59. Ko M, Huang Y, Jankowska A M, Pape U J, Tahiliani M, Bandukwala H S, An J, Lamperti E D, Koh K P, Ganetzky R, Liu X S, Aravind L, Agarwal S, Maciejewski J P, Rao A: Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature, 468: 839-843 (2010)
60. Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik V I, Kühn M W M, Rücker F G, Holzmann K, Paschka P, Kapp-Schwörer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk R F, Döhner H, Döhner K: Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood, 122: 100-108 (2013)
61. Krönke J, Schlenk R F, Jensen K-O, Tschürtz F, Corbacioglu A, Gaidzik V I, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih H R, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler H-G, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K: Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. Journal of Clinical Oncology, 29: 2709-2716 (2011)
62. Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, Nagae G, Yoshida H, Aburatani H, Koike K: Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Science, 103:
670-676 (2012)
63. Kunimoto H, Fukuchi Y, Sakurai M, Sadahira K, Ikeda Y, Okamoto S, Nakajima H: Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Scientific reports, 2:
273 (2012)
64. Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin S D, Benner R J, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S: Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica, 104: 113-119 (2019)
65. Lancet J E, Uy G L, Cortes J E, Newell L F, Lin T L, Ritchie E K, Stuart R K, Strickland S A, Hogge D, Solomon S R, Stone R M, Bixby D L, Kolitz J E, Schiller G J, Wieduwilt M J, Ryan D H, Hoering A, Banerjee K, Chiarella M, Louie A C, Medeiros B C: CPX-351 (cytarabine and daunorubicin) liposome
for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. Journal of Clinical Oncology, 36: 2684-2692 (2018)
66. Levis M J, Perl A E, Martinelli G, Cortes J E, Neubauer A, Berman E, Montesinos P, Baer M R, Larson R A, Chou W-C, Yokoyama H, Recher C, Yoon S-S, Hill J E, Rosales M, Liu C, Bahceci E: Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.. Journal of Clinical Oncology, 37: 7000 (2019)
67. Ley T J, Ding L, Walter M J, McLellan M D, Lamprecht T, Larson D E, Kandoth C, Payton J E, Baty J, Welch J, Harris C C, Lichti C F, Townsend R R, Fulton R S, Dooling D J, Koboldt D C, Schmidt H, Zhang Q, Osborne J R, Lin L, O’Laughlin M, McMichael J F, Delehaunty K D, McGrath S D, Fulton L A, Magrini V J, Vickery T L, Hundal J, Cook L L, Conyers J J, Swift G W, Reed J P, Alldredge P A, Wylie T, Walker J, Kalicki J, Watson M A, Heath S, Shannon W D, Varghese N, Nagarajan R, Westervelt P, Tomasson M H, Link D C, Graubert T A, DiPersio J F, Mardis E R, Wilson R K: DNMT3A mutations in acute myeloid leukemia. New England Journal of Medicine, 363: 2424-2433 (2010)
68. Lian C G, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, Lee C-w, Hu1 D, Lian B Q, Kleffel S, Yang Y, Neiswender J, Khorasani A J, Fang R, Lezcano C, Duncan L M, Scolyer R A, Thompson J F, Kakavand H, Houvras Y, .Zon L I, Jr. M C M, Kaiser U B, Schatton T, Woda B A, F.Murphy G, Shi Y G: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell, 150: 1135-1146 (2012)
69. Lin Y, Lin Z, Cheng K, Fang Z, Li Z, Luo Y, Xu B: Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis. Oncotarget, 8:
43295-43305 (2017)
70. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando S, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Bona E D, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih H, Cazzola M, Melillo L,
Carella A, Brandts C, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp M, Rambaldi A, Nasa G L, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk R, Platzbecker U: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. New England Journal of Medicine, 369: 111-121 (2013)
71. Lorsbach R, Moore J, Mathew S, Raimondi S, Mukatira S, Downing J: TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t (10; 11)(q22; q23). Leukemia, 17: 637-641 (2003) 72. Marcucci G, Haferlach T, Döhner H: Molecular genetics of adult acute
myeloid leukemia: prognostic and therapeutic implications. Journal of Clinical Oncology, 29: 475-486 (2011)
73. Marcucci G, Maharry K, Wu Y-Z, Radmacher M D, Mrózek K, Margeson D, Holland K B, Whitman S P, Becker H, Schwind S, Metzeler K H, Powell B L, Carter T H, Kolitz J E, Wetzler M, Carroll A J, Baer M R, Caligiuri M A, Larson R A, Bloomfield C D: IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 28: 2348-2355 (2010)
74. Mendler J H, Maharry K, Radmacher M D, Mrózek K, Becker H, Metzeler K H, Schwind S, Whitman S P, Khalife J, Kohlschmidt J, Nicolet D, Powell B L, Carter T H, Wetzler M, Moore J O, Kolitz J E, Baer M R, Carroll A J, Larson R A, Caligiuri M A, Marcucci G, Bloomfield C D: RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. Journal of Clinical Oncology, 30: 3109-3118 (2012)
75. Metzeler K H, Maharry K, Radmacher M D, Mrózek K, Margeson D, Becker H, Curfman J, Holland K B, Schwind S, Whitman S P, Wu Y-Z, Blum W, Powell B L, Carter T H, Wetzler M, Moore J O, Kolitz J E, Baer M R, Carroll A J, Larson R A, Caligiuri M A, Marcucci G, Bloomfield C D: TET2 mutations
improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 29: 1373-1381 (2011)
76. Mohr F, Döhner K, Buske C, Rawat V P: TET genes: new players in DNA demethylation and important determinants for stemness. Experimental Hematology, 39: 272-281 (2011)
77. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa M E, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, SherifIbrahim C H, Beran M, L.Levine R: Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell, 20: 11-24 (2011)
78. Mrózek K: Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Seminars in Oncology, 35: 365-377 (2008)
79. Mrózek K, Heerema N A, Bloomfield C D: Cytogenetics in acute leukemia.
Blood Reviews, 18: 115-136 (2004)
80. Mrózek K, Marcucci G, Nicolet D, Maharry K S, Becker H, Whitman S P, Metzeler K H, Schwind S, Wu Y-Z, Kohlschmidt J, Pettenati M J, Heerema N A, Block A W, Patil S R, Baer M R, Kolitz J E, Moore J O, Carroll A J, Stone R M, Larson R A, Bloomfield C D: Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. Journal of Clinical Oncology, 30: 4515 (2012)
81. Nakajima H, Kunimoto H: TET2 as an epigenetic master regulator for normal and malignant hematopoiesis. Cancer Science, 105: 1093-1099 (2014)
82. Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, Dombret H, Dreyfus F, Quesnel B, Geffroy S, Quentin S, Roche-Lestienne C, Cayuela J-M, Roumier C, Fenaux P, Vainchenker W, Bernard O A, Soulier J, Fontenay M, Preudhomme C: Incidence and prognostic value of
TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood, 116: 1132-1135 (2010)
83. Pabst T, Eyholzer M, Fos J, Müller B U: Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. British Journal of Cancer, 100: 1343-1346 (2009)
84. Pan F, Weeks O, Yang F-C, Xu M: The TET2 interactors and their links to hematological malignancies. IUBMB Life, 67: 438-445 (2015)
85. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V I, Paschka P, Roberts N D, Potter N E, Heuser M, Thol F, Bolli N, Gundem G, Loo P V, Martincorena I, Ganly P, Mudie L, McLaren S, O’Meara S, Raine K, Jones D R, Teague J W, Butler A P, Greaves M F, Ganser A, Döhner K, Schlenk R F, Döhner H, Campbell P J: Genomic classification and prognosis in acute myeloid leukemia. New England Journal of Medicine, 374: 2209-2221 (2016)
86. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Loo P V, Yoon C J, Ellis P, Wedge D C, Pellagatti A, Shlien A, Groves M J, Forbes S A, Raine K, Hinton J, Mudie L J, McLaren S, Hardy C, Latimer C, Porta M G D, O’Meara S, Ambaglio I, Galli A, Butler A P, Walldin G, Teague J W, Quek L, Sternberg A, Gambacorti-Passerini C, Cross N C P, Green A R, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton M R, Campbell P J: Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood, 122: 3616-3627 (2013)
87. Paschka P, Marcucci G, Ruppert A S, Whitman S P, Mrózek K, Maharry K, Langer C, Baldus C D, Zhao W, Powell B L, Baer M R, Carroll A J, Caligiuri M A, Kolitz J E, Larson R A, Bloomfield C D: Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Journal of Clinical Oncology, 26: 4595-4602 (2008)
88. Paschka P, Schlenk R F, Gaidzik V I, Habdank M, Krönke J, Späth L B, Kayser S, Zucknick M, Götze K, Horst H-A, Germing U, Döhner H, Döhner
K: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Journal of Clinical Oncology, 28: 3636-3643 (2010)
89. Paschka P, Schlenk R F, Gaidzik V I, Herzig J K, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne C-H, Brossart P, Held G, Horst H-A, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K: ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica, 100: 324-330 (2015)
90. Patel J P, Gönen M, Figueroa M E, Fernandez H, Sun Z, Racevskis J, Vlierberghe P V, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N D, Heguy A, Cherry A, Vance G, Higgins R R, Ketterling R P, Gallagher R E, Litzow M, van den Brink M R, Lazarus H M, Rowe J M, Luger S, Ferrando A, Paietta E, Tallman M S, Melnick A, Abdel-Wahab O, Levine R L: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. New England Journal of Medicine, 366: 1079-1089 (2012)
91. Perl A, Martinelli G, Cortes J, Neubauer A, Berman E, Paolini S, Montesinos P, Baer M, Larson R, Ustun C, Fabbiano F, Di Stasi A, Stuart R, Olin R, Kasner M, F, Chou W-C, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon S-S, Lee J-H, Pardee T, Fathi A, Liu C, Liu X, Bahceci E, Levis M:
Gilternitinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3MUT+) relapse/refactpry (R/R) acute myeloid leukemia (AML); Results from the pahse 3 admriral . Hemasphere, 3: 392-393 (2019) 92. Peterson L F, Zhang D-E: The 8; 21 translocation in leukemogenesis.
Oncogene, 23: 4255-4262 (2004)
93. Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Bona E D, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, Nasa G L, Fiedler W, Brossart P, Hertenstein B, Salih H R, Wattad M, Lübbert M, Brandts C
H, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani E M, Fozza C, D’Arco A M, Renzo N D, Cortelezzi A, Fabbiano F, Dö hner K, Ganser A, Dö hner H, Amadori S, Mandelli F, Ehninger G, Schlenk R F, Lo-Coco F:
Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial.
Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial.